R
RTW Investments, LP
+ Con en carteraZLAB
-11.31%
Rentabilidad a 3 meses
$23.190
-0.315 (-1.36%)Al cierre
Loading chart…
- Máximo
- 24.640
- Apertura
- 24.550
- Precio medio ponderado por volumen
- 23.66
- Volumen
- 843.23K
- Capitalización
- 1.73B
- Mínimo
- 23.140
- Importe
- 19.95M
- EV/EBITDA, TTM
- -6.11
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Análisis de IA of Zai Lab Ltd (ZLAB)
MantenerZai Lab Ltd is currently priced at $24.99, which is below the average analyst price target of $40.50, indicating potential upside. However, the stock has a low RSI of 43.54, suggesting it is nearing oversold conditions, but the recent insider selling has increased by 126%, which raises concerns about the stock's short-term stability.
Recomendaciones de analistas (3)
+106.68% de potencial alcista
Comprar
2 Comprar
1 Mantener
0 Vender
Actual: 23.19
Mínimo
25.70
Promedio
47.93
Máximo
74.00
JPMorgan
Sobreponderar
$36
2026-08-27
JPMorgan
2026-08-27
Precio objetivo
$36
Sobreponderar
Citi
Comprar
$45
2026-08-07
Citi
2026-08-07
Precio objetivo
$45
Comprar
Citi
Comprar
$44
2026-05-08
Citi
2026-05-08
Precio objetivo
$44
Comprar
JPMorgan
Sobreponderar
$32
2026-03-18
JPMorgan
2026-03-18
Precio objetivo
$32
Sobreponderar
Cantor Fitzgerald
Sobreponderar
$37
2026-02-27
Cantor Fitzgerald
2026-02-27
Precio objetivo
$37
Sobreponderar
Métricas de valoración
El PER previsto actual de Zai Lab Ltd (ZLAB) es 0.00, frente a su media de 5 años de -16.19.
Ballenas con ZLAB en cartera
Cronología de eventos
Noticias
9.010-14NewsfilterZai Lab to Present ZL-1503 Clinical Trial Data at ACAAI 2026
9.509-17CNBCChinese AI Companies Struggle with Revenue Growth
- 8.509-17Newsfilter
Chinese AI Models Generate Only 10% of Revenue Compared to U.S. Rivals
8.509-14CNBCZ.ai Plans to Raise $5 Billion Through Share Placement and Bonds
- 8.509-14Newsfilter
Z.ai Plans $5 Billion Fundraising, Shares Plunge Over 10%
Preguntas frecuentes sobre ZLAB, respondidas por Alphio AI
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Zai Lab Ltd is currently priced at $24.99, which is below the average analyst price target of $40.50, indicating potential upside. However, the stock has a low RSI of 43.54, suggesting it is nearing oversold conditions, but the recent insider selling has increased by 126%, which raises concerns about the stock's short-term stability.
3 analysts cover ZLAB: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 47.93.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.